- UHRA Home
- Browsing by Author
Browsing by Author "Oldgren, Jonas"
Now showing items 1-2 of 2
-
Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: An European and Asia-Pacific Expert Consensus Paper
Gorog, Diana; Gue, Ying X.; Chao, Tze-Fan; Fauchier, Laurent; Ferreiro, Jose Luis; Huber, Kurt; Konstantinidis, Stavros V; Lane, Deirdre A; Marin, Francisco; Oldgren, Jonas; Potpara, Tatjana; Roldan, Vanessa; Rubboli, Andrea; Sibbing, Dirk; Tse, Hung-Fat; Vilahur, Gemma; Lip, Gregory Y H (2022-03-22)Whilst there is a clear clinical benefit of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major bleeding events (especially ... -
Multicenter, Randomized, Active Comparator-Controlled, Double-Blind, Double-Dummy, Parallel Group, Dose-Finding Phase 2 Study Comparing the Safety of the Oral FXIa Inhibitor Asundexian with Apixaban in Patients with Atrial Fibrillation
Piccini, Jonathan P; Caso, Valeria; Connolly, Stuart J; Fox, Keith A A; Oldgren, Jonas; Jones, Schuyler; Gorog, Diana; Durdil, Vaclav; Viethen, Thomas; Neumann, Christoph; Mundl, Hardi; Patel, Manesh R (2022-04-09)Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation factor XIa (FXIa) inhibitor, might ...